Fluence Energy Gets UBS Upgrade: Stock Now Seen as Fairly Valued
2026 guidance cut sets a near-term earnings trough, creating a favorable base for 2027 growth reacceleration.
Already have an account? Sign in.
2026 guidance cut sets a near-term earnings trough, creating a favorable base for 2027 growth reacceleration.
A patient with highly active relapsing MS died 44 days after receiving BMS’s experimental CD19 CAR-T therapy zola-cel in an early-stage trial.
Bolt Biotherapeutics merges with Prana Therapies in a $120 million deal to advance PRA-216 through Phase 2 trials in asthma, COPD, and atopic dermatitis.
AbbVie’s Phase 3 HS data fell short of expectations, prompting two firms to downgrade Avalo Therapeutics and lower confidence in IL-1 approaches.
Be the first to know when deals break, stocks move, or biotech headlines hit.